Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A mini-review on platelet refractoriness.

Paolo Rebulla1

  • 1Centro Trasfusionale e di Immunologia dei Trapianti, Department of Transfusion Medicine, Tissue Repair and Transplant Coordination, Milan, Italy. prebulla@policlinico.mi.it

Haematologica
|February 16, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum: Quality and stability studies of red blood cell concentrates from umbilical cord blood compared to their adult counterparts.

Blood transfusion = Trasfusione del sangue·2026
Same author

Characterization of allogeneic platelet gel from adult donor blood and umbilical cord blood activated with locally prepared cryoprecipitate and thrombin: A pilot exercise.

Transfusion·2026
Same author

Meta-analysis of efficacy and safety of pathogen-reduced platelet components: Request for clarification.

Vox sanguinis·2024
Same author

In vitro regenerative effects of a pooled pathogen-reduced lyophilized human cord blood platelet lysate for wound healing applications.

Blood transfusion = Trasfusione del sangue·2024
Same author

Editorial Expression of Concern: Cell Lines Derived from Human Parthenogenetic Embryos Can Display Aberrant Centriole Distribution and Altered Expression Levels of Mitotic Spindle Check-point Transcripts.

Stem cell reviews and reports·2024
Same author

Quality and stability studies of red blood cell concentrates from umbilical cord blood compared to their adult counterparts.

Blood transfusion = Trasfusione del sangue·2024
Same journal

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026
Same journal

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Haematologica·2026
Same journal

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Haematologica·2026
Same journal

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Haematologica·2026
Same journal

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

Haematologica·2026
Same journal

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Haematologica·2026
See all related articles

Platelet refractoriness, a complication in chronic platelet transfusions, is often caused by clinical factors or medications. Immune causes like anti-HLA antibodies can be managed with HLA-matched platelets.

Area of Science:

  • Transfusion Medicine
  • Immunology
  • Hematology

Background:

  • Platelet refractoriness affects 5-15% of chronic platelet recipients.
  • It is characterized by inadequate post-transfusion platelet count increments.
  • This review covers literature from 2000-2004 on frequency, diagnosis, management, and cost.

Purpose of the Study:

  • To review the frequency, diagnosis, management, and cost of platelet refractoriness.
  • To analyze causes and potential solutions for post-transfusion platelet count increments.
  • To synthesize current knowledge on managing platelet support complications.

Main Methods:

  • Literature search of English publications (2000-2004) using PubMed.
  • Review of studies on platelet refractoriness definitions, causes, and management strategies.

Related Experiment Videos

  • Analysis of diagnostic criteria and therapeutic interventions.

    • Main Results:

    • Refractoriness defined by specific post-transfusion platelet counts (e.g., <2,500/µL at 24h).
    • Most cases linked to clinical or pharmacological factors.
    • Immune causes, particularly anti-HLA antibodies, are implicated in some cases.
    • HLA-matched platelet selection and cross-matching improve support in 2/3 of alloimmunized patients.

    Conclusions:

    • Anti-HLA alloimmunization is a less frequent but manageable cause of refractoriness.
    • Clinical condition and drug effects are primary unresolved causes of refractoriness.
    • Effective platelet support for refractory patients requires advanced strategies and resources.